Medtronic Unveils 'Artificial Pancreas' for Insulin Closed-Loop Management Ahead of MiniMed IPO

Jun 06, 2022 14:18 CST Updated 14:18

Medtronic

Chronic Disease Medical Device and Therapy Developer

On June 5, at the American Diabetes Association's annual scientific meeting, Dr. Robert Vigersky, Chief Medical Officer of Medtronic's diabetes business, described Medtronic's insulin delivery closed-loop system—commonly referred to as an artificial pancreas.The system can monitor the user's glucose levels and automatically adjust insulin as needed, without much input from the wearer.

Medtronic's closed-loop system starts with Medtronic's insulin pump and glucose sensor, combined with the latest version of the MiniMed 780G and Guardian 4 sensor. This management system has been proven to help users stay within the ideal blood glucose range for an average of 73% of the day, and even longer if patients use the system-recommended settings.

Reference Source:MedTrend Medical Trends

*Disclaimer: This article was written by an author who contributes to Sina Medicine News. The views expressed in this article are those of the author and do not represent the position of Sina Medicine News.